EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab.
Chemotherapy alone has limited ability to significantly improve survival in non-small lung cancer (NSCLC) beyond what has already been achieved. The epidermal growth factor (EGF) pathway plays a vital role in the pathogenesis and progression of NSCLC. Two classes of drugs inhibit the EGF receptor (EGFR) pathway: small molecules that inhibit the intracellular tyrosine kinase activity of the receptor, and monoclonal antibodies that target the extracellular domain in the ligand-binding region. Cetuximab is a human - mouse chimeric immunoglobulin G1 class monoclonal antibody directed against EGFR. Preclinical studies with cetuximab suggested that there was inhibition of growth of human NSCLC cell lines. Cetuximab is currently the focus of intense investigation in various patient populations with NSCLC. This review focuses on clinical trials of cetuximab in NSCLC and identifies future directions with this agent.
Reade
Chad A
CA
Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Ganti
Apar Kishor
AK
Semin Oncol. 2002 Feb;29(1 Suppl 4):3-14
11894009
Ann Oncol. 2004 Jan;15(1):28-32
14679115
Lung Cancer. 2009 May;64(2):194-8
18809226
N Engl J Med. 2005 Jul 14;353(2):123-32
16014882
Cancer Res. 1986 Nov;46(11):5592-8
3756906
J Clin Oncol. 1998 Jul;16(7):2459-65
9667264
Cancer Res. 1995 Dec 1;55(23):5536-9
7585629
Science. 2002 Jul 5;297(5578):63-4
12098689
J Clin Oncol. 2005 Apr 10;23(11):2493-501
15710947
J Clin Oncol. 2005 Dec 1;23(34):8786-93
16246975
J Clin Oncol. 2008 Feb 20;26(6):983-94
18281673
J Clin Oncol. 2008 Sep 10;26(26):4268-75
18626007
JAMA. 2003 Oct 22;290(16):2149-58
14570950
N Engl J Med. 2006 Dec 14;355(24):2542-50
17167137
N Engl J Med. 2003 Oct 9;349(15):1451-64
14534339
J Clin Oncol. 2007 Jun 1;25(16):2171-7
17538161
Cancer Cell. 2005 Apr;7(4):301-11
15837620
J Clin Oncol. 2005 Sep 1;23(25):5900-9
16043828
Clin Cancer Res. 2000 Feb;6(2):701-8
10690556
J Clin Oncol. 2000 Jan;18(1):122-30
10623702
BMC Cancer. 2008 Jun 10;8:169
18544172
J Clin Oncol. 2007 Apr 20;25(12):1545-52
17442998
J Clin Oncol. 2005 Dec 20;23(36):9089-96
16301597
N Engl J Med. 2002 Jan 10;346(2):92-8
11784875
Eur J Cancer. 1996 Nov;32A(12):2070-4
9014747
JAMA. 2004 Jul 28;292(4):470-84
15280345
Cancer Res. 2006 Apr 15;66(8):3992-5
16618717
Proc Natl Acad Sci U S A. 1986 Jun;83(11):3825-9
2424012
J Clin Oncol. 2003 Jun 15;21(12):2237-46
12748244
N Engl J Med. 2004 Dec 30;351(27):2883
15625347
J Clin Oncol. 2005 Oct 1;23(28):6829-37
15998907
Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11
15329413
J Clin Oncol. 2006 Nov 1;24(31):5034-42
17075123
Cancer Res. 1993 May 15;53(10 Suppl):2379-85
7683573
Science. 1989 May 12;244(4905):707-12
2470152
Cancer Res. 1999 Mar 15;59(6):1236-43
10096554
Br J Cancer. 1998 Feb;77(4):663-9
9484827
Br J Cancer. 1993 Jul;68(1):162-5
8391303
Clin Cancer Res. 1998 Jan;4(1):241-9
9516978
J Clin Oncol. 2005 Nov 1;23(31):8081-92
16204011
J Clin Oncol. 2000 Oct 1;18(19):3390-9
11013280
J Clin Oncol. 2005 Sep 1;23(25):5892-9
16043829
J Clin Oncol. 2005 Apr 10;23(11):2513-20
15738541
Crit Rev Clin Lab Sci. 2006;43(4):291-323
16769595
J Clin Oncol. 2004 Mar 1;22(5):785-94
14990633
Invest New Drugs. 1999;17(3):259-69
10665478
J Clin Oncol. 2008 Jul 10;26(20):3351-7
18612151
Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232
7612182
Semin Oncol. 2003 Feb;30(1 Suppl 1):3-11
12644979
Cancer Res. 2007 Mar 15;67(6):2643-8
17363584
J Biol Chem. 1990 May 15;265(14):7709-12
2186024
Br J Cancer. 2007 Apr 23;96(8):1166-9
17375050
J Natl Cancer Inst. 1987 Sep;79(3):403-7
3476783
Cancer Metastasis Rev. 1999;18(4):427-36
10855786
Cancer Treat Rev. 2006 Dec;32(8):630-6
17034953
Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37
16257339
Adv Cancer Res. 2000;77:25-79
10549355
J Clin Oncol. 2006 Nov 20;24(33):5253-8
17114658
J Clin Oncol. 2009 Jan 20;27(3):464-5; author reply 465-7
19064956
Cancer Treat Rev. 2009 Jun;35(4):340-4
19155139
Ann Oncol. 2007 Apr;18(4):752-60
17317677
J Clin Oncol. 2006 Oct 1;24(28):4539-44
17008692
Ann Oncol. 2008 Feb;19(2):362-9
17947225
Proc Natl Acad Sci U S A. 1989 Feb;86(3):925-9
2915986
Clin Cancer Res. 1997 Apr;3(4):515-22
9815714
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
18287387
Clin Cancer Res. 2001 Jul;7(7):1850-5
11448895
Clin Cancer Res. 1995 Nov;1(11):1311-8
9815926
J Thorac Oncol. 2008 Jun;3(6):648-51
18520806
Lancet Oncol. 2001 Sep;2(9):533-43
11905707
Lung Cancer. 1995 Apr;12 Suppl 1:S147-54
7551923
Thorax. 2006 Feb;61(2):140-5
16284218
J Clin Oncol. 2000 Feb;18(4):904-14
10673534
Endocr Relat Cancer. 2001 Mar;8(1):3-9
11350723
Semin Oncol. 2002 Oct;29(5 Suppl 14):38-44
12422312
Lancet Oncol. 2005 May;6(5):279-86
15863375
N Engl J Med. 2005 Jul 14;353(2):133-44
16014883
N Engl J Med. 2004 Jul 22;351(4):337-45
15269313
J Clin Oncol. 2004 Mar 1;22(5):777-84
14990632
N Engl J Med. 2004 May 20;350(21):2129-39
15118073
Curr Oncol Rep. 2002 Jul;4(4):317-24
12044241
J Clin Oncol. 2005 Mar 20;23(9):1803-10
15677699
Int J Biochem Cell Biol. 1999 Jun;31(6):637-43
10404636
Diagn Pathol. 2006 Aug 15;1:19
16911776
Mol Cancer Ther. 2007 Oct;6(10):2642-51
17913857
J Clin Oncol. 2007 Dec 20;25(36):5777-84
18089875
Exp Cell Res. 2003 Mar 10;284(1):31-53
12648464
J Clin Oncol. 2003 Oct 15;21(20):3798-807
12953099
Anticancer Res. 1993 Jul-Aug;13(4):1133-7
8394672
J Natl Cancer Inst. 2005 May 4;97(9):643-55
15870435
N Engl J Med. 2006 Feb 9;354(6):567-78
16467544
Chest. 2005 Jul;128(1):452-62
16002972
Cancer Res. 1993 Oct 1;53(19):4637-42
8402640
J Clin Oncol. 2008 Sep 10;26(26):4253-60
18779612
Annu Rev Biochem. 1988;57:443-78
3052279